Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Ammoxetine in Healthy Chinese Subjects
NCT03456388Phase 1Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Oct 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in major depressive disorder (MDD) comparing Ammoxetine with Placebo (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 8 days. Started Oct 2017; status: completed.
02
Drugs
ammoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03456388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03456388.